oxidopamine has been researched along with Mitochondrial Diseases in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Mitochondrial Diseases: Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of Parkinson's disease (PD) using stem cells has long been the focus of many researchers, but the ideal therapeutic strategy has not yet been developed." | 1.42 | Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease. ( Chang, KA; Choi, HS; Kim, HJ; Oh, JH; Park, HG; Ra, JC; Suh, YH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ay, M | 1 |
| Luo, J | 1 |
| Langley, M | 1 |
| Jin, H | 1 |
| Anantharam, V | 1 |
| Kanthasamy, A | 1 |
| Kanthasamy, AG | 1 |
| Lin, CY | 1 |
| Tsai, CW | 1 |
| Choi, HS | 1 |
| Kim, HJ | 1 |
| Oh, JH | 1 |
| Park, HG | 1 |
| Ra, JC | 1 |
| Chang, KA | 1 |
| Suh, YH | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Kim, J | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Ferrante, RJ | 1 |
4 other studies available for oxidopamine and Mitochondrial Diseases
| Article | Year |
|---|---|
Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
Topics: Adrenergic Agents; Animals; Antioxidants; Cell Line, Transformed; Cell Survival; DNA-Binding Protein | 2017 |
PINK1/parkin-mediated mitophagy pathway is related to neuroprotection by carnosic acid in SH-SY5Y cells.
Topics: Abietanes; Cell Line, Tumor; Cytochromes c; Humans; Membrane Potential, Mitochondrial; Mitochondria; | 2019 |
Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease.
Topics: Adipocytes; Animals; Disease Models, Animal; Dopaminergic Neurons; Electron Transport Complex I; Hum | 2015 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |